Addition to “The death of the strategy of classical chiral switches Is an exaggeration”

Additional text should be included following the Conclusion section as a Note Added after Issue Publication: According to this Viewpoint, the strategy of classical chiral switches of drugs and the development of racemic drugs which might later serve as candidates for chiral switches are alive. This message has since been challenged. Senkuttuvan et al. published in RSC Advances in October 2024 a mini-review entitled “The significance of chirality in contemporary drug discovery−a mini review”, concluding: “Over the last ten years, the traditional chiral swap method has vanished.” It should be noted, however, that the classical chiral switch levamlodipine maleate, indicated for the treatment of hypertension, was approved by the FDA in December 2019 (as indicated in our Viewpoint). Our Viewpoint highlighted the relevance and importance of the strategy of chiral switches, not only as a component of the strategy of drug repurposing/chiral-switches combination.